Sage Journals: Discover world-class research

Abstract

Several devices are available for infrainguinal endovascular therapy, with drug-eluting stents (DES) among the most promising. Bioresorbable vascular scaffolds (BVS) may further improve outcomes. We have liberally used in our practice coronary DES and BVS for infrainguinal endovascular therapy and hereby report our preliminary results. We conducted an observational study by retrospectively identifying characteristics of patients undergoing infrainguinal implantation of coronary DES or BVS. We compared the risk of major adverse events (MAE: death, amputation, or target vessel revascularization [TVR]) and components of MAE in the overall sample and after propensity matching. We included a total of 204 patients (207 limbs), 148 (72.5%) treated with DES and 56 (27.5%) with BVS. Bivariate analysis showed that TVR was less common in the DES group (41.9% vs 18.4%, P = .014). However, propensity-matched analysis showed nearly identical risks of MAE, amputation, TVR, or symptom burden with DES and BVS (all P > .05). In conclusion, the present pilot experience with coronary BVS suggests that they could provide acceptable results for infrainguinal endovascular procedures, comparable to those obtained by their metallic counterpart.

Keywords

bioresorbable vascular scaffold drug-eluting stent endovascular therapy peripheral artery disease superficial femoral artery

Get full access to this article

View all access options for this article.

References

Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte

Pomposelli

Clair

; Society for Vascular Surgery. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 suppl):2s–41s.

Peruzzi

Biondi-Zoccai

Frati

. Aortoiliac arteries: another Waterloo for transcatheter vs. open surgical therapy after aorta, cardiac valves, carotids, coronaries, femorals, and tibials? J Endovasc Ther. 2013;20(4):456–460.

Monaco

Stassano

Di Tommaso

. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. J Am Coll Cardiol. 2009;54(11):989–996.

Katsanos

Spiliopoulos

Karunanithy

Krokidis

Sabharwal

Taylor

. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59(4):1123–1133. e8.

Giordano

Biondi-Zoccai

Giordano

. Coronary Balloon-Expandable Drug-Eluting Stents for Focal Superficial Femoral Artery Disease: When is the Time Ripe for Challenging Conventional Wisdoms? J Transl Med Epidemiol. 2013;1:1003.

Giordano

Messina

Ferraro

. Feasibility of Coronary Balloon-Expandable Drug-Eluting Stent Implantation for Focal Superficial Femoral Artery Disease. J Cardiol Ther. 2014;1(1):12–16.

Biondi-Zoccai

Sangiorgi

Modena

. Devices for infrainguinal endovascular therapy: menu à la carte or table d’hôte? J Endovasc Ther. 2011;18(5):638–641.

Werk

Albrecht

Meyer

. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–840.

Dake

Ansel

Jaff

; Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61(24):2417–2427.

10.

Giordano

Messina

Biondi-Zoccai

. Successful treatment of a subclavian artery stenosis with a coronary bioresorbable vascular scaffold. J Endovasc Ther. 2016.

11.

Werner

Micari

Cioppa

. Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study. JACC Cardiovasc Interv. 2014;7(3):305–312.

12.

Werner

. Bioresorbable scaffolds for the SFA: new developments. J Cardiovasc Surg (Torino). 2014;55(4):455–459.

13.

Wiebe

Nef

Hamm

. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64(23):2541–2551.

14.

Palmerini

Benedetto

Bacchi-Reggiani

. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371–2382.

15.

ESPRIT I Update Presented for Abbott Vascular’s Esprit BVS. Web site. http://evtoday.com/2013/09/esprit-i-clinical-trialupdate. Posted October 9, 2013. Accessed March 3, 2016.

16.

Biondi-Zoccai

Romagnoli

Agostoni

. Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials. 2011;32(5):731–740.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB

Endovascular Therapy for Infrainguinal Artery Disease With Coronary Devices

Abstract

Keywords

Get full access to this article

References

Supplementary Material